Table 2.
Available data on pharmacologic management of PPP in boys with MAS.
| Drugs | Effects of therapy | N. of patients (range of age at the beginning of the treatment) | References |
|---|---|---|---|
| Testolactone + Flutamide | - Reduced growth velocity and testis volume. | 1 (8.5 year) | (56) |
| - Testolactone needed frequent daily administrations | |||
| - Flutamide associated with hypertransaminasemia and neutropenia | 1 (5 year) | (55) | |
| Testolactone + Spironolactone | - Improved BA/chronological age ratio and predicted FH | 3 (3–8 year) | (55) |
| Letrozole + Spironolactone | 1 (8 year) | ||
| Letrozole + Spironolactone + Flutamide | - PPP evolution and growth outcomes not reported | 1 (6 year) | (50) |
| Anastrozole + Bicalutamide | - Normalized growth velocity | 1 (4.6 year) | (57) |
| - Reduced androgenization | |||
| - Stabilized testicular volume | |||
| Ketoconazole + Cyproterone Acetate | - Decelerated growth velocity | 1 (4.6 year) | (58) |
| - Reduced both testicle size and testosterone and free testosterone serum levels | |||
| - Improved FH |
N, Number; BA, Bone Age; FH, Final height; yr, year; PPP, peripheral precocious puberty.